Evidence map›Paper›PMID 26976855›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.

Joseph L Usset, Rama Raghavan, Jonathan P Tyrer, Valerie McGuire, Weiva Sieh, Penelope Webb, Jenny Chang-Claude, Anja Rudolph, Hoda Anton-Culver, Andrew Berchuck and 40 more

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Impact of Gene-Environment Interactions on Cancer Development.International journal of environmental research and public health · 2020
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 8 countries.

Joseph L UssetDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Rama RaghavanDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas.
Jonathan P TyrerDepartment of Oncology, University of Cambridge Strangeways Research Laboratory, Cambridge, United Kingdom.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Weiva SiehDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Penelope WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Anja RudolphDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Hoda Anton-CulverDepartment of Epidemiology, University of California Irvine, Irvine, California.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Louise BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Anna DeFazioDiscipline of Obstetrics, Gynecology, and Neonatology, University of Sydney, Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia.
Jennifer A DohertyDepartment of Epidemiology, Geisel School of Medicine, Hanover, New Hampshire.
Robert P EdwardsDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Simon A GaytherDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Aleksandra Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Marc T GoodmanDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
Estrid HøgdallDepartment of Virus, Lifestyle, and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark. Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Allan JensenDepartment of Virus, Lifestyle, and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Sharon E JohnattyDivision of Genetics and Public Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Lambertus A KiemeneyDepartment of Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands.
Susanne K KjaerDepartment of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Melissa C LarsonDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Galina LurieCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Leon MassugerDepartment of Obstetrics & Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Francesmary ModugnoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Roberta B NessSchool of Public Health, The University of Texas, Houston, Texas.
Malcolm C PikeDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Susan J RamusDepartment of Preventive Medicine, University of Southern California, Los Angeles, California.
Mary Anne RossingDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, University of Washington, Seattle, Washington.
Joseph RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Honglin SongDepartment of Oncology, University of Cambridge Strangeways Research Laboratory, Cambridge, United Kingdom.
Pamela J ThompsonDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.
David J van den BergDepartment of Preventive Medicine, University of Southern California, Los Angeles, California.
Robert A VierkantDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Shan Wang-GohrkeDepartment of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Alice S WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii.
Anna H WuDepartment of Preventive Medicine, University of Southern California, Los Angeles, California.
Hannah YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Celeste Leigh PearceDepartment of Preventive Medicine, University of Southern California, Los Angeles, California. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan.
Joellen M SchildkrautDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
Paul PharoahDepartment of Oncology, University of Cambridge Strangeways Research Laboratory, Cambridge, United Kingdom. Department of Public Health and Primary Care, University of Cambridge Strangeways Research Laboratory, Cambridge, United Kingdom.
Ellen L GoodeDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Brooke L FridleyDepartment of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas. bfridley@kumc.edu.
Ovarian Cancer Association Consortium and the Australian Cancer Study
Mayo Clinic · USStanford Health Care · USUniversity of Southern California · USBridge University · SSCedars-Sinai Medical Center · USNational Cancer Institute · USUniversity of Kansas Medical Center · USCancer Center of Hawaii · USGerman Cancer Research Center · DEKing's College London · GBQIMR Berghofer Medical Research Institute · AURadboud University Nijmegen · NLUniversity of Pittsburgh · USDanish Cancer Society · DKDartmouth College · USDuke University · USHerlev Hospital · DKMemorial Sloan Kettering Cancer Center · USMillennium Institute · BRRoswell Park Comprehensive Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Northern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4M
The Molecular Epidemiology Of Ovarian CancerR01CA076016 · NCI · DUKE UNIVERSITY · PI SCHILDKRAUT, JOELLEN M. · 1998 to 2010
$6.2M
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPSR01CA058598 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GOODMAN, MARC T · 1993 to 2012
$4.6M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 16561NCI NIH HHS K07 CA143047NCI NIH HHS N01 PC067010NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA046592NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R13 CA110770NCI NIH HHS U01 CA069417NIA NIH HHS R01 AG061132
6 · The paper itself

Abstract

backgroundMany epithelial ovarian cancer (EOC) risk factors relate to hormone exposure and elevated estrogen levels are associated with obesity in postmenopausal women. Therefore, we hypothesized that gene-environment interactions related to hormone-related risk factors could differ between obese and non-obese women.

methodsWe considered interactions between 11,441 SNPs within 80 candidate genes related to hormone biosynthesis and metabolism and insulin-like growth factors with six hormone-related factors (oral contraceptive use, parity, endometriosis, tubal ligation, hormone replacement therapy, and estrogen use) and assessed whether these interactions differed between obese and non-obese women. Interactions were assessed using logistic regression models and data from 14 case-control studies (6,247 cases; 10,379 controls). Histotype-specific analyses were also completed.

resultsSNPs in the following candidate genes showed notable interaction: IGF1R (rs41497346, estrogen plus progesterone hormone therapy, histology = all, P = 4.9 × 10(-6)) and ESR1 (rs12661437, endometriosis, histology = all, P = 1.5 × 10(-5)). The most notable obesity-gene-hormone risk factor interaction was within INSR (rs113759408, parity, histology = endometrioid, P = 8.8 × 10(-6)).

conclusionsWe have demonstrated the feasibility of assessing multifactor interactions in large genetic epidemiology studies. Follow-up studies are necessary to assess the robustness of our findings for ESR1, CYP11A1, IGF1R, CYP11B1, INSR, and IGFBP2 Future work is needed to develop powerful statistical methods able to detect these complex interactions. IMPACT: Assessment of multifactor interaction is feasible, and, here, suggests that the relationship between genetic variants within candidate genes and hormone-related risk factors may vary EOC susceptibility. Cancer Epidemiol Biomarkers Prev; 25(5); 780-90. ©2016 AACR.

Indexed as

FemaleGene-Environment InteractionHumansMiddle AgedObesityOvarian NeoplasmsPolymorphism, Single NucleotideRisk Factors

Identifiers

PMID26976855
PMCPMC4873330
OpenAlexW2295115544

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.